Overview

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Status:
Completed

Trial end date:
2020-05-27

Target enrollment:

Participant gender:

Summary

The key purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of TBPM-PI-HBr compared to IV ertapenem, in subjects with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP).

Phase:

Phase 3

Details

Lead Sponsor:

Spero Therapeutics

Treatments:

Ertapenem